April, 2008
Doing Better at Doing Good
Nature Biotechnology
Global health initiatives should place greater emphasis on mechanisms for encouraging small and medium-sized biotech enterprises to participate in the fight against neglected diseases.
March 13, 2008
Voucher Senate Sponsor Seeks New Incentive for Drugmakers
BioWorld Today
The likeability of the U.S. by foreign nations could increase if Americans broadened their efforts in global health initiatives, such as developing drugs to tackle diseases that affect poor populations, said Sen. Sam Brownback (R-Kan.).
March 12, 2008
Priority Review Vouchers the Next 'Golden Ticket'?
BioWorld Today
Political scientists looking for a model to streamline the legislative process might ponder the efforts of a group of Duke University professors.
June 1, 2007
TB Gets Deadlier and Closer
Atlanta Journal Constitution
BVGH's Chris Earl and Joelle Tanguy (Global Business Coalition) join forces on this op-ed about the looming global threat posed by drug-resistant TB.
February 13, 2007
Panel Deliberates Ideas to Fund Global Health Products
BioWorld
BVGH's VP of Business Development, Julie Klim, leads a panel on innovative financing mechanisms for global health products like an investment fund.
February 12, 2007
Creating a $1.5B Market
BioCentury
BVGH's Wendy Taylor discusses the pilot AMC program for pneumococcal vaccines.
February 9, 2007
Vaccinating the World
Business Week
BVGH Founder, Wendy Taylor, discusses the need for market incentives for vaccine development and the importance of the AMC pilot launch
.
January 11, 2007
Increased Innovation Needed in the Fight Against Epidemics
Seattle Post-Intelligencer
BVGH CEO, Chris Earl and Board member Melinda Moree, write an Op-ed about the need for increased innovation in response to the White House Summit on Malaria.
January, 2007
Innovation and Reduced Risk Remain Keys to 2007 Funding
BioExecutive International
BVGH CEO, Chris Earl, makes the case for investment in neglected dieseases like TB.
December 29, 2006
NDT Funding Strategies Seek to Bring Bench Progress to Bedside [PDF, 123KB]
BioWorld Today
BVGH CEO, Chris Earl, discusses neglected tropical disease funding opportunities.
November 1, 2006
Getting Your Gates
The Scientist
BVGH CEO, Chris Earl, talks about the entrance of non-profits into drug development work.
September 19, 2006
Bets on Biotech
U.S. News & World Report
BVGH CEO, Chris Earl, is quoted in this latest article on biomedical philanthropy.
July 3, 2006
A Market Remedy That Can Bring Vaccines to the Poor
Financial Times
Together with Harvey Bale, Director-General of the International Pharmaceutical Manufacturers and Associations (IFPMA), BVGH CEO, Christopher D. Earl, encourages the G8 to use the St. Petersburg summit to launch a pilot AMC.
June 22, 2005
$5.4M Pledged To Spur Drugs For Diseases That Afflict Poor [PDF, 54KB]
USA Today BVGH's newest grant - a $5.4 million grant from the Bill & Melinda Gates Foundation - is announced.
June 21, 2005
Funds Steer Biotech Drugs to Poor [PDF, 506KB]
The
Wall Street Journal
BVGH's newest grant - a $5.4 million grant from the Bill & Melinda Gates Foundation - is announced.
March 28, 2005
Third World Solutions [PDF, 1.23MB]
BioCentury
Karen Bernstein looks at the changing landscape of global health product development opportunities and the emerging role biotech companies are playing in this field. The article highlights the work that BVGH is doing to uncover and build market opportunities for products that address neglected diseases.
March 18, 2005
BIO Ventures Pushes Biotech Involvement in Global Issues [PDF, 92 KB]
BioWorld Today
BVGH's mission and activities are highlighted, as the organization moves into its first full year of operations.
September, 2004
Developing Markets [PDF, 522KB]
Nature Biotechnology
Wendy Taylor, Executive Director of BVGH, responds to
an August editorial in the September Letters to the Editor section.
August, 2004
Boldness, but with realism [PDF, 568KB]
Nature Biotechnology
This editorial applauds BVGH for "daring to conceive that biotech and the developing world can be allies against the scourge of disease" and points out the challenges presented by inadequate distribution systems in resource-poor settings.
June
7,
2004
BIO’s
Global Health Venture [PDF, 35 KB]
BioCentury
The Biotechnology Industry Organization (BIO), together with the Bill & Melinda Gates Foundation and the Rockefeller Foundation, is set to announce the creation of BIO Ventures for Global Health (BVGH).
June
6,
2004
Medical Aid on Way for Poorer
Nations
The Washington Post The Biotechnology Industry Organization (BIO), together with the Bill & Melinda Gates Foundation and the Rockefeller Foundation, is set to announce the creation of BIO Ventures for Global Health (BVGH).
May
28,
2004
Bringing Biotechnology to
Developing Countries
BIO News The Biotechnology Industry Organization (BIO), together with the Bill & Melinda Gates Foundation and the Rockefeller Foundation, is set to announce the creation of BIO Ventures for Global Health (BVGH).
